Compare Las Vegas Sands Corp. (LVS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Moderna, Inc. — how do they compare? Las Vegas Sands Corp. trades at $45.5 (market cap $30.36B), while Moderna, Inc. trades at $59.66 (market cap $23.60B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| LVS | MRNA | |
|---|---|---|
Market Cap | $30.36B | $23.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $81.80 |
52-Week Low | $44.78 | $22.36 |
Enterprise Value | $42.75B | $19.70B |
Dividend Yield | 2.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.47, showing modest 0.24% daily gains amid bearish technical signals. The company demonstrates strong fundamental performance with consistent earnings beats, including Q1 2026 EPS of $0.91 exceeding expectations by 20%. Revenue growth accelerated to $13.02B in 2025, while maintaining solid profitability with 13.41% net margins. Recent corporate actions include a $0.30 dividend payment and $740M share repurchases in Q1 2026.
Analyst consensus remains strongly bullish with 61% buy ratings and $64.75 price target representing 42% upside. Key risks include high debt levels at 73.15% debt-to-asset ratio and potential regulatory headwinds in gaming markets. The combination of strong earnings momentum, attractive valuation at 16.9 P/E, and positive institutional sentiment supports a constructive outlook despite near-term technical weakness.
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
